DigiDiab Pilot: Impact Study Hospital
- Conditions
- Type 2 Diabetes
- Registration Number
- NCT06605872
- Lead Sponsor
- Medical University of Graz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria:<br><br> - informed consent obtained after being advised of the nature of the study<br><br> - a documented history of type 2 diabetes prior to inclusion or new-onset<br> hyperglycaemia which requires s.c. insulin therapy during hospital stay<br><br> - admission to either surgical or internal medicine ward<br><br> - an expected length of hospital stay for at least 48 hours after enrolment<br><br>Exclusion Criteria:<br><br> - type 1 diabetes mellitus<br><br> - intravenous insulin therapy<br><br> - hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require<br> intravenous insulin therapy<br><br> - continuous subcutaneous insulin infusion<br><br> - gestational diabetes or pregnancy<br><br> - known or suspected allergy to insulin<br><br> - total parenteral nutrition<br><br> - any mental condition rendering the patient incapable of giving his/her consent<br><br> - any disease or condition which according to the investigator or treating physician<br> would interfere with the trial or the safety of the patient<br><br>Inclusion and exclusion criteria will be the same as above for the retrospective CG with<br>the exception of:<br><br> - period of time will be from September 2022 to September 2023<br><br> - no informed consent will be obtained from the retrospective CG
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method Usability;Safety;Efficacy